THE CBD INITIATIVE
As a leader in nutraceutical development, Inergetics is launching the CBD Initiative focused on exploring the growth, extraction and development of cannabinoid based nutritional products. While THC (tetrahydrocanabinol) found in medical marijuana was the focus of attention in the past, evolving research on other non-psychoactive cannabinoids such as CBD (cannabidiol) addressing a variety of clinical conditions including pain, nausea, seizures, eye and brain health are on the forefront of evidenced based medicine and nutritional science. Acknowledging the wealth of published data unraveling the medical benefits of cannabinoids, Inergetics plans to be a leader in providing various marketplaces with pharmaceutical grade nutritional products.
Helping us to better understand cannabinoids and the advances that are taking place in the laboratory and physician’s office, Inergetics has assembled a collective of accomplished physicians and PhD’s to man its Medical/Scientific Advisory Board. With much of the new literature aimed at advances in laboratory techniques for isolation, detection and extraction of cannabinoids; awareness of the various cannabinoids expressing therapeutic effects; and clinical application, we look forward to our Board to provide their experience and insights to help guide us in our product development.
Inergetics is proud to work with its strategic partner Terra Tech (TRTC) to embark on the CBD Initiative to provide patients and consumers the first comprehensive line of CBD-based nutraceuticals.
Carl Germano, RD, CNS, CDN
Chief Science Officer, Research & Product Development
As Chief Science Officer for Inergetics, Mr. Germano is a Board Certified Clinical Nutritionist and Registered Dietician with over 30 years’ experience using innovative, complementary nutritional therapies in private practice and in product development. He holds a Master’s degree in clinical nutrition from New York University and has dedicated his efforts to research and new product development for the nutritional industry (medical foods, dietary supplements and functional beverages), where he has been instrumental in bringing over state-of-the-art nutritional ingredients and over 200 nutritional formulations to market. Mr. Germano continues his efforts in new product development at Inergetics and is responsible for providing the company with the next generation of clinically relevant ingredients and formulations. He has also held a progressive Nutrition Therapy Center practice for many years and has extensive experience in the nutritional treatment of disease.
In addition to his vast clinical experience, he has served as a VP of R&D or as new product development consultant for some of the largest dietary supplement companies in the industry, including Solgar Vitamin & Herb Company, Bluebonnet Nutrition, Ajinomoto’s Amino Vital, Isocell, Nutratech and Country Life Vitamins. He recently launched his new book The Misled Athlete and is also the author of the best selling trade books: Natures Pain Killers, The Osteoporosis Solution and The Brain Wellness Plan and is a frequent featured radio guest.
Joseph McSherry, MD
Dr. McSherry is a neurologist who has extensive knowledge of research involving the medical benefits of cannabis and its cannabinoids for pain management, medicinal and therapeutic use. He is a widely recognized academic expert on medical cannabis/cannabinoids and its many health benefits, and is also involved in several community service initiatives including his service on the State of Vermont’s Marijuana Oversight Committee. Dr. McSherry is the author of numerous academic and public presentations on the medical use of cannabis/cannabinoids in general and as it relates to cancer and other specific medical conditions. He received the Outstanding Physician Advocate Award from the Washington, D.C.-based Marijuana Policy Project in 2010.
Dr. McSherry is a practicing physician licensed in both Vermont and New York, currently serving as an Attending Neurologist at Fletcher Allen Health Care in Burlington, Vermont. Additionally, he serves as a Clinical Associate Professor of Neurology at the University of Vermont, College of Medicine, where he has been teaching since 1977. He previously served as the Associate Medical Director of Blue Cross Blue Shield of Vermont, and as Assistant Professor of Neurology at Baylor College of Medicine in Houston, Texas.
Dr. McSherry received his B.A. from Harvard College in Cambridge, Massachusetts, and his M.D. and Ph.D. from Baylor College of Medicine in Houston, Texas. He is a member of the American Academy of Neurology, the American Clinical Neurophysiology Society, the Eastern EEG Society, the Northern New England Neurological Society and the Vermont Medical Society. In addition, Dr. McSherry is board certified by the American Board of Clinical Neurophysiology, the American Board of Psychiatry & Neurology, with Added Qualification in Neurophysiology, as well as the Part I Academy for Healthcare Management.
Mark Wallace, MD
Dr. Wallace is an acclaimed anesthesiologist specializing in pain management, with deep experience researching innovative pain treatments and performing in-depth clinical trials on all types of pain. He is board certified in both anesthesiology and pain medicine in the State of California, and is on faculty at the University of California San Diego Health System and the Veterans Affairs San Diego Healthcare System.
At UC San Diego, Dr. Wallace serves as the chair of the Division of Pain Medicine and is a Professor of Clinical Anesthesiology. He is also the Director, Division of Clinical Research, UCSD Clinical and Translational Research Institute. He is actively involved in all aspects of clinical care, graduate medical education/training and research. Dr. Wallace’s research on pain medicine has been widely published in an extensive array of peer-reviewed medical journals and books. He is also the recipient of numerous grants, including grants from Pfizer, Medtronic and Abbott.
Dr. Wallace is a Diplomate of the American Board of Pain Medicine, the American Board of Anesthesiology and the National Board of Medical Examiners. He is also on the Board of Directors of the American Pain Society, and a member of several other professional societies including the American Academy of Pain Medicine and the International Association for the Study of Pain, among others. From 2010 to 2013, Dr. Wallace was named “Top Doc” in San Diego Magazine’s “Physicians of Exceptional Excellence” annual survey performed in collaboration with the San Diego County Medical Society. He was also the recipient of the Leonard Tow Humanism in Medicine Award in 2012.
Dr. Wallace earned his M.D. from Creighton University School of Medicine, completed his residency in anesthesiology at the University of Maryland and also completed a NIH Training Grant Fellowship and a Pain Fellowship at the University of California, San Diego.
Michelle Sexton, ND
Dr. Sexton is a highly-respected expert in the medicinal applications of cannabis, naturopathic medicine and the phytochemistry of plant medicine, with more than 15 years of experience in natural, herbal and holistic medicine. She currently serves as the Executive Medical Research Director at the Center for the Study of Cannabis and Social Policy in Seattle. For the past several years, she owned and operated Phytalytics LLC, doing business as PhytaLab, a phytochemical analysis company dedicated to developing and perfecting analytical platforms for the quality control of medical and adult use cannabis and related products in Washington State.
Dr. Sexton is an active authority on medical cannabis, having published research in scientific journals, presented a number of abstracts on the medical application of cannabis and cannabinoids, particularly for patients with multiple sclerosis, provides continuing education for healthcare providers on the clinical use of Cannabis, and serves as an expert witness for medical cannabis cases. She is a member of the Society of Cannabis Clinicians, the International Cannabinoid Research Society (ICRS), and the International Association for Cannabinoid Medicine (IACM). She is on the board of directors for Americans for Safe Access Foundation.
Dr. Sexton earned her B.S. in Horticulture from Texas Tech University, graduating cum laude. She received her doctorate in Naturopathic Medicine from Bastyr University in Seattle, Washington, and completed her postdoctoral fellowship at the University of Washington.
Justin Fischedick, PhD
Dr. Fischedick is a respected expert in the therapeutic and medicinal properties of the chemical components of plants, specifically cannabis. He brings years of experience in advanced chromatography and spectrometry, including proven abilities in the isolation of natural products for scientific and medical analysis.
Dr. Fischedick is currently a Postdoctoral Research Associate at the Institute of Biological Chemistry at Washington State University, and has authored or co-authored several scientific articles on cannabis, cannabinoids and terpenoids published in top scientific and medical journals. He has presented his scientific research at a number of national and international conferences including the Phytochemical Society of North America conference, the International Conference on Natural Products Research and the International Association for Cannabinoids as Medicine (IACM) conference.
Dr. Fischedick is also a member of the Phytochemical Society of North America, the Society for Medicinal Plant and Natural Products Research and the Central New York Mycological Society. He earned his B.S. in Biology from the State University of New York College of Environmental Science and Forestry (SUNY-ESF), and his M.Sc. and Ph.D. in Biology with a focus on Natural Products from the Leiden University, Institute of Biology in The Netherlands.
Yu Shao, PhD
Dr. Shao has extensive experience in product research and development across many areas of health and wellness, specializing in pharmaceutical extraction methods and plant biochemistry – as well as formulating herbal and botanical nutritional products. He brings almost two decades of expertise in these fields working with a variety of global firms, including Glaxo Smith Kline, Wyeth (now Pfizer), and Merck, directing the launch of more than 30 innovative new products for these companies.
Dr. Shao has an impressive record of isolating and extracting new herbal, vitamin and pharmaceutical products to market. His recent experience includes eight product launches in eight years at Glaxo Smith Kline U.S. and 25 new products in four-plus years at Glaxo Smith Kline China. He has served in a range of senior R&D roles during his 13-year career at Glaxo Smith Kline, including Head of R&D for the Consumer Healthcare business in China; Group Leader/Director, New Weight Loss Product Development; Principal Scientist, Smoking Control/Pain Management; and Senior Development Scientist. Dr. Shao has also served as Manager of Herbal and Vitamin R&D at Wyeth (now Pfizer) and as a Senior Scientist developing botanical extracts for dietary supplements at Pure World Botanicals. Additionally, he is the inventor and author of more than 60 pharmaceutical patents.
Dr. Shao received his Ph.D. in Natural Products Chemistry from the Shanghai Institute of Materia Medica, his M.A. in Organic Chemistry from Lanzhou University and his B.S. in Chemistry from Yangtze University. He also served as a Postdoctoral Fellow in Natural Products Chemistry at Rutgers University.